BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Clin Oncol. Oct 24, 2026; 17(10): 125097
Published online Oct 24, 2026. doi: 10.5306/wjco.125097
Table 4 Immunohistochemical characteristics of defined subtypes within poorly cohesive carcinoma

Evaluable cases

SRC
SRC/PCC-NOS
PCC-NOS
P value
n70171133
CEA, n/N (%)209-6/42 (14.3) 5/89 (5.6) 6/78 (7.7) 0.416
-/+4/42 (9.5) 7/89 (7.9) 6/78 (7.7)
+26/42 (61.9) 72/89 (80.9) 61/78 (78.2)
++1/42 (2.4) 2/89 (2.2) 1/78 (1.3)
+++5/42 (11.9) 3/89 (3.4) 4/78 (5.1)
Ki67, mean (SD)3550.40 (0.24)0.52 (0.22)0.55 (0.20)< 0.001
HER2, n/N (%)350-44/62 (71.0) 106/162 (65.4) 82/126 (65.1) 0.122
+14/62 (22.6)42/162 (25.9) 25/126 (19.8)
++2/62 (3.2) 11/162 (6.8) 18/126 (14.3)
+++2/62 (3.2) 3/162 (1.9) 1/126 (0.8)
P53, n/N (%)260-12/47 (25.5) 33/113 (29.2) 26/100 (26.0) 0.244
-/+3/47 (6.4) 9/113 (8.0) 2/100 (2.0)
+16/47 (34.0) 33/113 (29.2) 23/100 (23.0)
++5/47 (10.6) 11/113 (9.7) 10/100 (10.0)
+++11/47 (23.4) 27/113 (23.9) 39/100 (39.0)
EGFR, n/N (%)111-3/18 (16.7) 13/45 (28.9) 9/48 (18.8) 0.545
-/+1/18 (5.6) 4/45 (8.9) 2/48 (4.2)
+14/18 (77.8) 28/45 (62.2) 37/48 (77.1)
MLH1, n/N (%)63-0/7 (0.0) 0/32 (0.0) 4/24 (16.7) 0.031
+7/7 (100.0) 32/32 (100.0) 20/24 (83.3)
MSH2, n/N (%)63+7/7 (100.0) 32/32 (100.0) 24/24 (100.0)
MSH6, n/N (%)63-0/7 (0.0) 0/32 (0.0) 1/24 (4.2) 0.438
+7/7 (100.0) 32/32 (100.0) 23/24 (95.8)
PMS2, n/N (%)63-0/7 (0.0) 0/32 (0.0) 4/24 (16.7) 0.031
+7/7 (100.0) 32/32 (100.0) 20/24 (83.3)
PD-1, n/N (%)38-6/6 (100.0) 13/15 (86.7) 14/17 (82.4) 0.546
+0/6 (0.0) 2/15 (13.3) 3/17 (17.6)
PD-L1, n/N (%)171CPS < 121/23 (91.3) 68/78 (87.2) 51/70 (72.9) 0.035
CPS ≥ 12/23 (8.7) 10/78 (12.8) 19/7 (27.1)


Write to the Help Desk